Lynch Ryan
See Remarks
Lynch Ryan has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Sep 18, 2026.
On the most recent filing, Lynch Ryan is listed as See Remarks at CRESCENT BIOPHARMA, INC. Inside the rolling window, Lynch Ryan reported no open-market purchases and 2 open-market sales totaling $13K in CBIO. The largest disclosed transaction in the window is a sale of 465 CBIO shares on Jun 22, 2026, worth $8K.
Companies traded
Other insiders at CBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$13K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lynch Ryan made?
Lynch Ryan has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Lynch Ryan trade?
Lynch Ryan has filed SEC Form 4 disclosures for 1 company, including CBIO.
When was Lynch Ryan's most recent SEC Form 4 filing?
Lynch Ryan's most recent SEC Form 4 filing on Tracefour is dated Sep 18, 2026.
What is Lynch Ryan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lynch Ryan is listed as See Remarks.
What is Lynch Ryan's total buy and sell value in the current window?
Inside the rolling retention window, Lynch Ryan bought $0 and sold $13K based on SEC Form 4 filings.
What was Lynch Ryan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 465 CBIO shares on 2026-06-22, worth $8K, per SEC Form 4 filings.